Once the cen­ter of a pub­lic storm of anger over de­nied drug, Chimerix now can’t even re­cruit pa­tients for their tri­als

Five years af­ter Chimerix found it­self at the cen­ter of a hur­ri­cane of pub­lic anger over its ini­tial re­fusal to pro­vide their lead ex­per­i­men­tal drug to a dy­ing child, the biotech says now that they can’t even re­cruit pa­tients for their stud­ies. 

That’s forc­ing them to scrap all their late-stage clin­i­cal de­vel­op­ment work on the drug — the oral an­tivi­ral brin­cid­o­fovir — and lay off half the re­main­ing staff at the Durham, NC-based biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER